Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma.

Ondine BecquartBastien OrianoStéphane DalleLaurent MortierMarie Thérèse LecciaCaroline DutriauxSophie DalacHenri MontaudiéJulie De QuatrebarbesFlorence Brunet-PossentiPhilippe SaiagThierry LesimpleMarie Beylot-BarryFrançois AubinPierre-Emmanuel StoebnerJean-Philippe ArnaultBrigitte DrenoRaphael PorcherCeleste LebbeBernard Guillot

Published in: Cancers (2021)

This study on a large multicentric cohort is the first to assess that TT is well tolerated in elderly BRAF-mutated patients such as in patients younger than 65. Efficacy was similar between groups with outcomes reaching those from pivotal studies. There is thus no argument against using TT in elderly people, although an onco-geriatric opinion is welcome for the most vulnerable.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
systematic review
type diabetes
patient reported outcomes
adipose tissue
middle aged
hip fracture
wild type
case control